Overview
Cyendiv contains Nintedanib, an oral tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF), non-small cell lung cancer (NSCLC), and systemic sclerosis-associated interstitial lung disease (SSc-ILD). Nintedanib works by targeting multiple kinases involved in the fibrosis process, slowing down the progression of lung disease and potentially improving overall lung function. It is typically used in combination with other therapies for its full effect.





